Form 4: Quest Diagnostics Director Lassiter Wright III Reports Phantom Stock Unit Acquisition

Director Lassiter Wright III reports acquisition of phantom stock units through elective deferrals and dividend reinvestment in Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors.

Summary

• On April 1, 2025, Wright L. Lassiter III, a director of Quest Diagnostics Inc., acquired 169 phantom stock units.
• These units were obtained through elective deferrals of cash compensation under the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors.
• The phantom stock units become payable in cash upon Lassiter's termination of service as a director.
• As of the transaction date, Lassiter holds a total of 359.911 phantom stock units, including those credited through dividend reinvestment transactions.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a standard compensation practice. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The phantom stock units become payable in cash upon the reporting person's termination of service as a director.

Industry Context

This Form 4 filing is a routine disclosure related to director compensation and holdings, common among publicly traded companies. It provides transparency into the equity-based compensation of company insiders.

Key Dates

Keywords

Quest Diagnostics, Director, Lassiter Wright III, Phantom Stock Units, Form 4, Deferred Compensation, Dividend Reinvestment